Century Therapeutics Highlights CNTY-813 Data at ADA
PHILADELPHIA, Pennsylvania, April 2026 Century Therapeutics announced that its investigational program CNTY-813 has been selected for oral presentation at...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
PHILADELPHIA, Pennsylvania, April 2026 Century Therapeutics announced that its investigational program CNTY-813 has been selected for oral presentation at...
WILMINGTON, DE — November 21, 2025 — Telomir Pharmaceuticals announced new preclinical findings showing that its investigational compound Telomir-1...
Philadelphia, November 10, 2025 — Verismo Therapeutics, a clinical-stage biotechnology company pioneering KIR-CAR T cell therapies, presented compelling preclinical...
October 14, 2025 | Düsseldorf, Germany — Abalos Therapeutics announced the publication of preclinical proof-of-concept data in Cell Reports...
GRAND CAYMAN, Cayman Islands, Sept. 11, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA...
